According to a new study published in PLOS ONE, using blood samples collected, over can average of 15 years before brain tumor diagnosis to analyze relationships between 12 allergy-related proteins, researchers at Ohio State University looked at how those relationships were different between people later diagnosed with brain tumors and cancer-free groups.
A new study, featured in Neurology, analyzed data from over 14,300 people in the United States and Canada found that childhood cancer survivors who have had one stroke face a heightened risk of having another.
According to The Tribune, researchers at Mayo Clinic and the University of California San Francisco have shown that sorting patients based on the molecular makeup of brain tumors instead of tumor appearance is possible.
According to The Huffington Post, the AARP Forum on Family Caregiving held in Washington, DC, on July 8 spotlighted the largely ignored issue of family care and potential policies that will offer solutions and funding.
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma.